Excess body weight was responsible for 3.9 percent of cancer globally, or 544,300 cases, in 2012, according to a new report.
The report, published Wednesday in the journal CA: A Cancer Journal for Clinicians, also highlights a relationship between obesity and the risk of 13 cancers, including postmenopausal breast cancer and liver cancer, and a probable relationship with three others, including prostate cancer.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
